Innosphere launches non-pharmaceutical ADHD clinical trial at top-tier research hospitals seeking pediatric patients
BERLIN, May 2, 2024 /PRNewswire/ - Innosphere Engineering Ltd (Innosphere or the Company), a medical device company developing non-pharmaceutical treatments for ADHD, is pleased to announce the launch of recruitment for a randomized, sham-controlled, double-blind clinical trial examining the safety and effectiveness of Novostim 2 transcranial Random Noise Stimulation (tRNS) on ADHD symptoms in pediatric patients (7 – 12 years).
- BERLIN, May 2, 2024 /PRNewswire/ - Innosphere Engineering Ltd (Innosphere or the Company), a medical device company developing non-pharmaceutical treatments for ADHD, is pleased to announce the launch of recruitment for a randomized, sham-controlled, double-blind clinical trial examining the safety and effectiveness of Novostim 2 transcranial Random Noise Stimulation (tRNS) on ADHD symptoms in pediatric patients (7 – 12 years).
- 2016 data from the Centers for Disease Control and Prevention estimates 6 million children had been given diagnoses of ADHD and 62 percent were taking medication, often stimulants.
- "Pharmaceuticals and specifically stimulants have been the standard of care in ADHD for decades, with challenging side effects well documented," says Rami Shacour, co-Founder and CEO of Innosphere.
- "Building on our previous successful clinical trial , we are ecstatic to provide a non-medicated option for children in need and look forward to a swift and impactful trial."